Development of Escitalopram Genomic Device by Using Candidate Gene Approach and Genome-Wide Scanning

Samsung Medical Center

Status: Unknown

Conditions: Continuous Antidepressant Abuse; Adverse Reaction to Drug; Depression

Treatments: Drug: Escitalopram

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT00935246

2008-12-042

Details and patient eligibility

About

To reveal the genetic determinants of the treatment outcome of escitalopram in depressed patients (by using candidate gene approach and whole genome scanning).

Full description

The purposes of this study are:

1. To reveal the genetic determinants of the treatment outcome of escitalopram in depressed patients (by using candidate gene approach and whole genome scanning)
2. To improve the success rate of escitalopram treatment response for depressed patients

Enrollment: 202 estimated patients

Sex: All

Ages: 19 to 89 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Eligible patients were enrolled in the clinical trials program of hte Samsung Medical Center Geropsychiatry and Affective Disorder Clinics(Seoul, Korea). They received a semistructured diagnostic interview, the Samsung Psychiatric Evaluation Schedule. The affective disorder section of the Samsung Psychiatric Evaluation Schedule uses the Korean version of the structured clinical interview for the diagnostic and statistical manual of mental disorders, Fourth edition.
2. interview with one more patient's family member for objective diagnosis and final diagnosis decision by agreements of two more psychiatric physicians

Exclusion criteria

1. received psychotropic medication within 2 weeks of the study or fluoxetine within 4 weeks
2. potential study participants for pregnancy, significant medical conditions, abnormal laboratory baseline values, unstable psychiatric features(eg.suicidal), history of alcohol of drug dependence, seizures, head trauma with loss of consciousness, neurological illness, or concomitant Axis I psychiatric disorder.

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

202 participants in 2 patient groups

Antidepressant treated group

Experimental group

Description:

Antidepressant treated group: depressed patients treated with Escitalopram

Treatment:

Drug: Escitalopram

other antidepressant treated group

No Intervention group

Description:

other Antidepressant treated group: depressed patients treated with other antidepressant without escitalopram